In 2011 CHEManager, a leading European magazine for the chemical and pharmaceutical industries (www.chemanager-online.com), has published a list of foreign pharmaceutical companies with representative offices in Russia, who are considering the possibility of local production of medicines (drugs).
Building partnerships with local companies — is one way to ensure guaranteed sale of drugs by foreign companies in Russia, which seeks to reduce dependence on imports. Global pharmaceutical companies have committed to investing at least 1 billion USD in manufacturing, packaging, research and development in Russia.
GlaxoSmithKline. November 26, 2011 in Moscow signed an agreement to establish a strategic alliance between the JSC "Binnofarm" (a subsidiary of AFK "System") and "GSK" (UK). It involves the transfer of technology to localize the production of innovative vaccines for biopharmaceutical complex "Binnofarm" in Zelenograd. "GSK" will provide technology transfer, training and audits of manufacturing processes to bring them into compliance with GMP, as well as long-term supply of antigens for the needs of the Russian production.
AstraZeneca in June 2011 announced the creation of a new research center in St. Petersburg. Previously, the company has committed to invest USD 150 million in the construction of a new plant in Russia.
The U.S. biotech company Genzyme announced plans to conduct joint research with the Russian high-tech center "KhimRar", including joint research relevant to Russia 3-5 therapeutic areas and technology transfer.
Pfizer, the largest global pharmaceutical company, has entered into an agreement with the Russian manufacturer of biotech drugs "NPO Petrovax Farm" on the production of innovative Pfizer’s pneumococcal vaccine on the production facilities "Petrovax Farm" in the Moscow region.
Orion Corporation — The leading Finnish concern for health in Northern Europe — announced a provisional results in the negotiations for the acquisition of assets with several Russian companies. The company has already implemented several joint projects with Russian manufacturers of packing products.
Novartis — Swiss drug maker — announced plans to invest USD 500 million over five years to the development of local production, R & D and public health in Russia.
European pharmaceutical company Ipsen says the intention to consider production project in Russia, including a partnership with the Russian pharmaceutical producers.
As reported by Reuters in July 2011, one of the top managers Teva in Russia, the company plans to invest USD 100 million in the creation of drug production in Russia, which will allow a 3-fold increase in sales in 2015.
Novo Nordisk — A world leader in the production of insulin — said it will invest USD 80-100 million in the construction of the first plant in Russia.
Group Sanofi back in 2009, signed a Memorandum of Understanding with "Prominvest", a 100%-owned subsidiary of the Russian State Corporation "Russian Technologies", which confirms the intention of Sanofi participate in the project "Pharmpolis." To implement the project recently acquired by Sanofi engages in Russia a new modern plant for the production of insulin (JSC "Bioton Vostok") as a pilot initiative.
The Swiss company Nycomed a group Takeda underway is building a plant for the production of liquid sterile products and solid medicines in the Yaroslavl region. Investment in construction is estimated at EUR 75 million as the company plans to run the plant in 2014.
Company Joh son & Johnson entered into an agreement with JSC "Pharmstandard" on the outer packaging anti-cancer drug Velcade in the facilities "Pharmstandard".
Krka (Slovenia). The plant LLC "Krka Rus" — one of the most modern factories in Russia, which has a production capacity of 600 million tablets and 240 million capsules per year. The plant embodies the modern concept of production that meets the requirements of EC GMP and the Russian pharmaceutical standards. In January 2011, construction began on the 2nd stage of the plant LLC "KRKARUS." The planned deadline of the second stage — in 2013-2014.
Gedeon Richter (Hungary). More than 15 years working in the Russian pharmaceutical plant JSC "Gedeon Richter-RUS" (Moscow Region, Egorievskiy district). In addition, the company is a minority shareholder in Russia’s largest farmholdinga "leaked" (about 4% of the shares). The representative of Gedeon Richter has confirmed its intention to bring the share to 5%.
The French company Servier in 2007 opened a manufacturing facility for the production of branded products for the local market in Sofyino (Moscow reg.). In the center are virtually all phases of the production cycle, except for synthesis of pharmaceutical substances. Investment in the construction of the plant was EUR 40 million
STADA CIS — The first Russian holding company as part of the international group STADA. It brings together leading companies in the pharmaceutical market in Russia — "Nizhpharm", "Makiz Pharma" and "Hemofarm".
The head of the German pharmaceutical company «Schening-Berlin» Dr. Gerd Goebel and plant manager SUE Gudermesski plant Medinstrument Masaip Shamurzaev sign documents on the creation of a joint German-Russian company «Shening». The new joint venture will encourage the pharmaceutical industry of the Chechen Republic and serve as a powerful impetus for the creation of high-tech pharmaceutical industry that combines a century of experience of the company and the German quality in the manufacture of medicines.